Novel Treatment Modalities for High-Risk Neuroblastoma : Studies in Animal Models

摘要: BACKGROUND: High-risk neuroblastoma has an overall five-year survival of less than 40%, indicating a need for new treatment strategies such as angiogenesis inhibition. Recent studies have shown that chemotherapeutic drugs can inhibit if administered in continuous schedule. The aim this study was primarily to characterize tumor spread orthotopic, metastatic model aggressive, MYCN-amplified and secondarily the effects daily administration agent CHS 828 on angiogenesis, growth, spread. METHODS: human cells (IMR-32, 2 x 10(6)) were injected into left adrenal gland SCID mice through flank incision. Nine weeks later, laparotomy performed confirm establishment estimate volume. Animals randomized either with (20 mg/kg/day; p.o.) or vehicle control. Differences between groups volume analyzed by Mann-Whitney U test using Fisher's exact test. p < 0.05 considered statistically significant. RESULTS: orthotopic resembled clinical respect site, growth Treatment resulted regression (p 0.001) reduction viable fraction 0.05) correlation reduced plasma levels putative marker chromogranin A 0.001). These due increased cell death angiogenesis. No treatment-related toxicities observed. CONCLUSION: animal is therefore clinically relevant examining malignancy. Our results indicate scheduling may be beneficial treating patients high-risk neuroblastoma.